Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

735 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party.
Collette L, Sylvester RJ, Stenning SP, Fossa SD, Mead GM, de Wit R, de Mulder PH, Neymark N, Lallemand E, Kaye SB. Collette L, et al. Among authors: kaye sb. J Natl Cancer Inst. 1999 May 19;91(10):839-46. doi: 10.1093/jnci/91.10.839. J Natl Cancer Inst. 1999. PMID: 10340903 Clinical Trial.
Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group.
de Wit R, Stoter G, Sleijfer DT, Kaye SB, de Mulder PH, ten Bokkel Huinink WW, Spaander PJ, de Pauw M, Sylvester R. de Wit R, et al. Among authors: kaye sb. Br J Cancer. 1995 Jun;71(6):1311-4. doi: 10.1038/bjc.1995.254. Br J Cancer. 1995. PMID: 7540039 Free PMC article. Clinical Trial.
Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study.
Kaye SB, Mead GM, Fossa S, Cullen M, deWit R, Bodrogi I, van Groeningen C, Sylvester R, Collette L, Stenning S, De Prijck L, Lallemand E, deMulder P. Kaye SB, et al. J Clin Oncol. 1998 Feb;16(2):692-701. doi: 10.1200/JCO.1998.16.2.692. J Clin Oncol. 1998. PMID: 9469359 Clinical Trial.
Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.
de Wit R, Sylvester R, Tsitsa C, de Mulder PH, Sleyfer DT, ten Bokkel Huinink WW, Kaye SB, van Oosterom AT, Boven E, Vermeylen K, Stoter G. de Wit R, et al. Among authors: kaye sb. Br J Cancer. 1997;75(3):432-5. doi: 10.1038/bjc.1997.71. Br J Cancer. 1997. PMID: 9020492 Free PMC article. Clinical Trial.
Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.
de Wit R, Stoter G, Kaye SB, Sleijfer DT, Jones WG, ten Bokkel Huinink WW, Rea LA, Collette L, Sylvester R. de Wit R, et al. Among authors: kaye sb. J Clin Oncol. 1997 May;15(5):1837-43. doi: 10.1200/JCO.1997.15.5.1837. J Clin Oncol. 1997. PMID: 9164193 Clinical Trial.
Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
Horwich A, Sleijfer DT, Fosså SD, Kaye SB, Oliver RT, Cullen MH, Mead GM, de Wit R, de Mulder PH, Dearnaley DP, Cook PA, Sylvester RJ, Stenning SP. Horwich A, et al. Among authors: kaye sb. J Clin Oncol. 1997 May;15(5):1844-52. doi: 10.1200/JCO.1997.15.5.1844. J Clin Oncol. 1997. PMID: 9164194 Free article. Clinical Trial.
735 results